نتائج البحث - "Ronnie Shapira-Frommer"

1

Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer

المساهمون: Vergote, I, Ray-Coquard, I, Anderson, D, Cantuaria, G, Colombo, N, Garnier-Tixidre, C, Gilbert, L, Harter, P, Hettle, R, Lorusso, D, Maenpaa, J, Marth, C, Matsumoto, K, Ouwens, M, Poveda, A, Raspagliesi, F, Rhodes, K, Rubio Perez, M, Shapira-Frommer, R, Shikama, A, Sikorska, M, Moore, K, Disilvestro, P, Tampere University, Clinical Medicine, Department of Gynaecology and Obstetrics

المصدر: European Journal of Cancer. 157:415-423

مصطلحات موضوعية: Oncology, Cancer Research, Piperazines, Placebos, chemistry.chemical_compound, Olaparib, Maintenance therapy, 3123 Gynaecology and paediatrics, Antineoplastic Combined Chemotherapy Protocols, Medicine, Ovarian Neoplasms, education.field_of_study, BRCA1 Protein, BRCA mutation, Hazard ratio, Middle Aged, Newly diagnosed, Progression-Free Survival, Bevacizumab, Female, Life Sciences & Biomedicine, medicine.drug, medicine.medical_specialty, 3122 Cancers, Population, Poly(ADP-ribose) Polymerase Inhibitors, Placebo, Maintenance Chemotherapy, Double-Blind Method, Ovarian cancer, Internal medicine, Humans, education, Response Evaluation Criteria in Solid Tumors, Aged, Neoplasm Staging, BRCA2 Protein, Science & Technology, business.industry, medicine.disease, chemistry, Mutation, Phthalazines, business, Follow-Up Studies

وصف الملف: Print-Electronic; STAMPA; fulltext

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2a311faad749e0197dd728b39586e37
https://doi.org/10.1016/j.ejca.2021.08.023

View record from ScienceDirect

Full Text via ClinicalKey

2

58 KEYNOTE-826: Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer

المؤلفون: Domenica Lorusso, Nicoletta Colombo, A. Arkhipov, V. Cáceres, Pamela Salman, Kan Li, E Hoyos Usta, Vincent Castonguay, M. Olivera Hurtado de Mendoza, Bradley J. Monk, Mahmut Gumus, Kosei Hasegawa, Eduardo Yanez, Coraline Dubot, S. Toker, Krishnansu S. Tewari, Ronnie Shapira-Frommer, Stephen Michael Keefe, Vanessa Samouëlian

المصدر: Late breaking abstracts.

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::7de7787d957ce6d2ed53d222878fa798
https://doi.org/10.1136/ijgc-2021-esgo.641

3

Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2

المساهمون: Ovarian Cancer Action

المصدر: Gynecologic oncology, vol 161, iss 3
Gynecol Oncol

مصطلحات موضوعية: 0301 basic medicine, Indoles, Administration, Oral, Carcinoma, Ovarian Epithelial, Gastroenterology, chemistry.chemical_compound, 0302 clinical medicine, Ovarian Epithelial, Medicine, Ovarian carcinoma, Cancer, Ovarian Neoplasms, education.field_of_study, biology, BRCA1 Protein, Obstetrics and Gynecology, Middle Aged, Ovarian Cancer, Oncology, Local, 030220 oncology & carcinogenesis, Area Under Curve, 6.1 Pharmaceuticals, Administration, Female, Drug, Safety, Oral, medicine.medical_specialty, Efficacy, Population, Oncology and Carcinogenesis, Cmax, Aspartate transaminase, Article, Exposure, Dose-Response Relationship, Paediatrics and Reproductive Medicine, 03 medical and health sciences, Rare Diseases, Clinical Research, Internal medicine, Humans, Pharmacokinetics, 1112 Oncology and Carcinogenesis, Oncology & Carcinogenesis, education, Rucaparib, Adverse effect, Dose Modification, Platinum, Aged, Dose-Response Relationship, Drug, business.industry, Carcinoma, Evaluation of treatments and therapeutic interventions, 030104 developmental biology, Neoplasm Recurrence, Orphan Drug, Alanine transaminase, chemistry, biology.protein, 1114 Paediatrics and Reproductive Medicine, Neoplasm Recurrence, Local, business, Recurrent Ovarian Carcinoma

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc43e336cb1d5e9ac5a3b43adc1f8b64
http://hdl.handle.net/10044/1/88601

4

Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial

المساهمون: Institut du Cancer de Montpellier (ICM), Sarah Cannon Research Institute [Nashville, Tennessee], BC Cancer Agency (BCCRC), Universitaetsklinikum Hamburg-Eppendorf = University Medical Center Hamburg-Eppendorf [Hamburg] (UKE), Royal Marsden NHS Foundation Trust, Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia [Brescia], Chaim Sheba Medical Center, H. Lee Moffitt Cancer Center and Research Institute, Dana-Farber Cancer Institute [Boston]

المصدر: Gynecologic Oncology
Gynecologic Oncology, Elsevier, 2019, 152, pp.560-567. ⟨10.1016/j.ygyno.2018.12.009⟩

مصطلحات موضوعية: 0301 basic medicine, [SDV]Life Sciences [q-bio], humanos, Medizin, 0302 clinical medicine, Piperidines, Clinical endpoint, piperidinas, PARP inhibitors, mediana edad, Aged, 80 and over, Ovarian Neoplasms, anciano, education.field_of_study, Hazard ratio, quimioterapia de mantenimiento, Obstetrics and Gynecology, Middle Aged, adulto, 3. Good health, Oncology, 030220 oncology & carcinogenesis, Cohort, Female, Adult, medicine.medical_specialty, Indazoles, Population, Niraparib, Poly(ADP-ribose) Polymerase Inhibitors, Placebo, Maintenance Chemotherapy, 03 medical and health sciences, Breast cancer, Ovarian cancer, Internal medicine, Older patients, medicine, Humans, Patient Reported Outcome Measures, education, Adverse effect, Aged, business.industry, neoplasias ováricas, medicine.disease, 030104 developmental biology, Neoplasm Recurrence, Local, business, gBRCA mutation

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb9ad9c2c774b562481bb27f33aac39c
https://doi.org/10.1016/j.ygyno.2018.12.009

View record from ScienceDirect

Full Text via ClinicalKey

5

Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety

المؤلفون: Lara Maloney, Yvette Drew, Alexandra Leary, Ana Oaknin, Ronnie Shapira-Frommer, Iain A. McNeish, Sandra Goble, Rebecca Kristeleit, Judith Balmaña, Susan M. Domchek, Amit M. Oza, Isabelle Ray-Coquard, Domenica Lorusso, Terri Cameron, Jonathan A. Ledermann

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb51ea06975e756387e07067569e12bd
http://hdl.handle.net/10044/1/74597

6

Pembrolizumab for vulvar squamous cell carcinoma: results from the phase 2 KEYNOTE-158 study

المؤلفون: Kevin Norwood, Sarina Anne Piha-Paul, Ludmila Manzyuk, Fan Jin, Ronnie Shapira Frommer, Linda Mileshkin, Antoine Italiano, Eugenia Girda, Patrick A. Ott, Lei Xu, Jose Lopez Martin, Marloes G J van Dongen, Matthew Burge, Nicolas Penel

المصدر: Gynecologic Oncology. 162:S44

مصطلحات موضوعية: medicine.medical_specialty, education.field_of_study, Vulvar Squamous Cell Carcinoma, business.industry, Population, Obstetrics and Gynecology, Phases of clinical research, Cancer, Pembrolizumab, Vulvar cancer, medicine.disease, Gastroenterology, Oncology, Internal medicine, medicine, Clinical endpoint, Vulvar Carcinoma, education, business

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::f6d78e2fafac5e8e9495592e7468d1b7
https://doi.org/10.1016/s0090-8258(21)00728-9

View record from ScienceDirect

Full Text via ClinicalKey

7

Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer

المؤلفون: Ignace Vergote, David A. Parry, Michael Friedlander, Clare L. Scott, Anitra Fielding, Ronnie Shapira-Frommer, Philipp Harter, Ursula A. Matulonis, Daniela Matei, Jonathan A. Ledermann, Helen Mann, Werner Meier, Gordon J. S. Rustin, Tamar Safra, Charlie Gourley, Bryan M. Bennett, Stuart Spencer

المصدر: British Journal of Cancer
Ledermann, J A, Harter, P, Gourley, C, Friedlander, M, Vergote, I, Rustin, G, Scott, C, Meier, W, Shapira-frommer, R, Safra, T, Matei, D, Fielding, A, Bennett, B, Parry, D, Spencer, S, Mann, H & Matulonis, U 2016, ' Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer ', British Journal of Cancer . https://doi.org/10.1038/bjc.2016.348

مصطلحات موضوعية: Adult, 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, endocrine system diseases, FACT-O questionnaire, BRCA, Population, Antineoplastic Agents, Placebo, olaparib, Piperazines, Olaparib, law.invention, Placebos, Young Adult, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Breast cancer, Maintenance therapy, Randomized controlled trial, Quality of life, law, Internal medicine, medicine, Humans, education, Aged, Aged, 80 and over, Ovarian Neoplasms, education.field_of_study, maintenance treatment, business.industry, Middle Aged, medicine.disease, Clinical trial, ovarian cancer, 030104 developmental biology, quality of life, chemistry, 030220 oncology & carcinogenesis, Clinical Study, Phthalazines, Female, Neoplasm Recurrence, Local, business